- Conditions
- Refractory Multiple Myeloma
- Interventions
- Tivantinib, Diagnostic laboratory biomarker analysis, Questionnaire administration, Quality-of-life assessment
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 4,778
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more
- Conditions
- Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
- Interventions
- MRTX1719
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Lone Tree, Colorado • Jacksonville, Florida + 20 more
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Interventions
- AMG 479
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Boston, Massachusetts
- Conditions
- Metastatic Pancreatic Cancer, Pancreatic Cancer
- Interventions
- IMMU-107, placebo, Gemcitabine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 42
- States / cities
- Gilbert, Arizona • Duarte, California • Long Beach, California + 33 more
- Conditions
- Advanced Solid Tumor
- Interventions
- IMP1734
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 18 more
- Conditions
- Multiple Myeloma, Amyloidosis, Plasma Cell Leukemia
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 5,000 participants
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma
- Interventions
- THOR-707, Pembrolizumab, Cetuximab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Duarte, California • Orlando, Florida • Seattle, Washington
- Conditions
- Cholangiocarcinoma
- Interventions
- Nab-Paclitaxel and Gemcitabine
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 24
- States / cities
- Denver, Colorado • Chicago, Illinois • Oak Lawn, Illinois + 17 more
- Conditions
- Colorectal Cancer
- Interventions
- PolyPEPI1018 CRC Vaccine
- Biological
- Lead sponsor
- Treos Bio Zrt
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Solid Tumors
- Interventions
- PF-03814735
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
- Interventions
- TKI258
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 15 more
- Conditions
- Multiple Myeloma
- Interventions
- Oral microbiota assessment, Comprehensive chemical gustometry, Measurement of salivary flow, Surveys assessing taste disturbances
- Diagnostic Test · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- IMO-8400
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Atlanta, Georgia • Decatur, Illinois + 9 more
- Conditions
- Psoriasis
- Interventions
- CP-690,550
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,867 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
- Conditions
- Non Small Cell Lung Carcinoma NSCLC
- Interventions
- Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple
- Interventions
- ICG Intervention, Near Infrared Camera
- Drug · Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- Lactobacillus rhamnosus GG
- Dietary Supplement
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Health Status Unknown, Elevated PSA
- Interventions
- Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, MRI Ultrasound Fusion Guided Biopsy
- Procedure · Other · Diagnostic Test
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 1 more
- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
- Biological · Drug · Radiation
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • La Jolla, California • Orange, California + 10 more
- Conditions
- Carcinoma, Squamous Cell, Anorectal Cancer
- Interventions
- Pembrolizumab, Lenvatinib
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neurofibromatosis 1, Malignant Peripheral Nerve Sheath Tumor (MPNST) of Soft Tissue (Diagnosis), Atypical Neurofibroma
- Interventions
- Whole Body Magnetic Resonance Imaging
- Diagnostic Test
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Standard of care
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York